The Research Gap
She Was Not
In the Study.
For decades, medicine built its knowledge of the human body from one body type. The treatments, the dosages, the diagnostic criteria — built on data that excluded half the population. This is not history. This is still happening.
I was six years old when a hospital diagnosed me with thalassemia. I was twenty-five when I found out. The file existed. The diagnosis existed. The knowledge that could have explained nineteen years of exhaustion, depression, and dismissal — existed. Nobody told me. That is not an accident of individual incompetence. It is the product of a medical system that was not built to look for answers in a body like mine.
This post is not about me. It is about the architecture of a problem that runs through every hospital, every drug trial, every diagnostic criterion, every textbook still in use in every medical school in the world. Modern medicine built its knowledge of the human body from a male body. And then it applied that knowledge to everyone.
Women are not small men. We metabolise drugs differently. We experience symptoms differently. We carry different risk profiles. Our immune systems, our brains, our hormonal systems interact with every major biological process we have. And for most of the history of clinical medicine, none of this was considered important enough to study. I am not interested in softening that sentence.
Who Was in the Room?
Drag the timeline — watch who was, and was not, counted as human
The exclusion was not accidental. It was written down. And the consequences were not contained to the decades in which it was official policy — they are embedded in the reference ranges, the diagnostic criteria, the drug dosages, and the clinical decision-making frameworks that are still in use today. This is what makes the research gap an ongoing emergency rather than a historical embarrassment.
The exclusion was policy. In 1977, the FDA issued guidelines explicitly recommending the exclusion of women of childbearing potential from Phase I and early Phase II drug trials. The stated rationale was protecting foetuses. The actual consequence was sixteen years of federally endorsed drug development based almost entirely on male biology. The drugs developed in those years are still in use today. The 1993 NIH Revitalization Act mandated the inclusion of women — but a Harvard Medical School study found that as of 2019, twenty-six years later, women were still substantially underrepresented in trials for leading diseases. The law changed the requirement. It did not change the assumption. [1]
The heart attack that looks like anxiety. Women are 50% more likely to be misdiagnosed following a heart attack. Women under 55 are seven times more likely to be sent home from the ER without cardiac testing. The most severe type of heart attack is 59% more likely to produce an incorrect initial diagnosis in women than in men. Over one decade in England and Wales, these failures contributed to more than 8,000 avoidable deaths. The reason is not physician incompetence. It is diagnostic criteria built from male patient data — and a medical education system that still teaches the "classic" heart attack presentation, which is predominantly male. [2]
Pain is not believed when it comes from a woman. A 2024 study in PNAS found that 38% of women received pain medication in the ER, compared to 47% of men reporting equivalent pain. Women spent 30 extra minutes in unaddressed pain. Women's pain scores were 10% less likely to be recorded at all. The identified mechanism: a gender-pain exaggeration bias — the documented assumption that women overreport. The historical term for this assumption is hysteria. It is not historical. [3]
80% of autoimmune patients are women. The research does not reflect this. More than 80 autoimmune conditions exist. Approximately 80% of all patients are women. The average time to diagnosis is 4.6 years and five different doctors. Lupus, MS, Hashimoto's, Sjögren's, rheumatoid arthritis — predominantly female, chronically underfunded, historically dismissed as psychosomatic. [4]
Side effects are not equal. A 2018 analysis found that women are 50–75% more likely than men to experience adverse drug reactions. The most common explanation: standard doses were calibrated for a 70-kilogram male body. Women metabolise many drugs more slowly, have different body composition ratios, and experience hormonal fluctuations that alter drug metabolism across the cycle. None of this was systematically measured during the drug development process. The dose you are prescribed was not designed for you. [5]
The medical system did not forget about women. It decided, explicitly and in writing, that women's bodies were too complicated to study. Then it treated us with the knowledge it had built without us.
The Funding Gap
100 dots = NIH research budget · Toggle to see distribution · Click any condition for the data
Female-dominant diseases are underfunded relative to burden in 75% of cases (Mirin, 2021).
There is a pattern so consistent across female-dominant conditions that it has its own name in the research literature: the diagnostic delay. The years between symptom onset and diagnosis in conditions like endometriosis, lupus, ME/CFS, and Hashimoto's are not explained by complex symptom pictures or difficult biology. They are explained by a clinical culture in which women's pain and fatigue are default-attributed to stress, anxiety, and the ordinary demands of female life before they are investigated with the same rigour applied to male patients.
The average diagnostic delay for endometriosis is 7 to 9 years. For lupus it is 6 years. For ME/CFS, it is 5 years and an average of 7 physicians. These are not obscure conditions. Endometriosis affects 190 million women. Lupus affects five times more women than men. ME/CFS affects women at three times the male rate. The delay is not a consequence of rarity. It is a consequence of whose pain the diagnostic framework was built to investigate.
Seven to nine years. That is the average time between the first symptom of endometriosis and the diagnosis. Seven to nine years of pain that was real, documented, and physically present — dismissed, repeatedly, by a diagnostic system that was not designed to look for it.
What the research gap produces, in practice, is not just missed diagnoses. It produces a specific kind of medical encounter: one in which a woman arrives with symptoms, is tested against reference ranges built from populations that include millions of iron-deficient women, receives an ECG interpreted against a QT interval threshold calibrated to the male heart, is offered a standard drug dose calculated for a 70-kilogram male body, and leaves with a normal result and a recommendation to reduce her stress. The gap is not a gap in a research database. It is a gap in the clinical encounter. And it has a cost that is measured in years.
Some conditions are funded so far below their disease burden that the disparity is not a gap — it is a chasm. Most women who have one of these have never been told how little research exists on what they are living with.
Ten Conditions. One System That Failed Them.
Click any card to see what is known — and what is still, inexcusably, not funded
Every drug trial, every animal study, every cell culture experiment should analyse and report results by sex. The failure to do this has produced medical knowledge not generalisable to half the population. No one has been held accountable for the cost of that failure. In 2016, the NIH mandated sex as a biological variable in preclinical research. Compliance is inconsistent. The culture of the default male body does not change by policy alone.
Endometriosis: $4.30 per patient per year. HIV/AIDS: approximately $2,583 per patient per year. Both serious diseases. Both with dedicated advocacy movements. The difference in funding is not explained by scientific priority or by the severity of the conditions. It is explained by whose body was considered worth studying first, and whose voice was heard loudest when the budgets were set.
Medical schools still teach the "classic" heart attack presentation — chest pain, left arm — as the default. This is predominantly male. Women more frequently present with nausea, jaw pain, fatigue, and breathlessness. As long as the male presentation is taught as the standard, physicians will keep sending women home. Reference ranges, diagnostic criteria, drug dosages — all of these require sex-disaggregated recalibration. Not as an addendum. As the standard.
The most powerful thing that can change is the number of women who walk into a clinical encounter knowing what the research gap means for them. Who know to ask whether their drug was tested on female subjects. Who know that a "normal" ferritin result and a "normal" TSH and a "normal" QT interval all carry specific caveats about what "normal" was built from. Who name their symptoms specifically and refuse the attribution of stress until a differential diagnosis has been properly investigated. Knowledge is not a substitute for systemic change. It is the starting point for demanding it.
The research gap is now widely acknowledged. Reviews are published. Reports are commissioned. Conferences are held. And then the funding allocations are made, and the same conditions are underfunded in the same proportions as the previous year. Acknowledgement without accountability changes nothing. What changes things is specific, time-bound funding commitments, mandatory sex-disaggregated reporting in all federally funded research, and consequences — clinical, legal, and institutional — for diagnostic systems that continue to fail female patients at documented and measurable rates.
I am not going to end this post by telling you to be your own advocate. That advice, while true, places the burden of a structural failure on the people it is failing. The responsibility for closing the research gap belongs to the institutions, the funding bodies, the medical schools, and the regulatory frameworks — not to individual women asking their GP whether the drug they have just been prescribed was tested on people with their biology.
That said: knowledge changes what is possible in a clinical encounter. Knowing that the QT interval reference range has a sex-specific threshold changes what you ask when you are prescribed a drug that prolongs it. Knowing that the ferritin lower limit of normal was derived from a population in which iron deficiency had become statistically common changes what you do when your result comes back with no flag. Knowing that the "classic" heart attack presentation is male changes what you say in the ER at 2am when you are nauseated and your jaw hurts and someone is about to send you home.
The research gap produced a generation — several generations — of women who were failed by a diagnostic system that was not built for them. That cannot be undone. What can change is what the next encounter looks like, and the one after that, and the standard of care that the women reading this will demand for themselves and for the people they love. That is not a small thing. It is, in fact, the mechanism by which every structural change that has ever happened in medicine has begun.
I found my thalassemia diagnosis in a file at twenty-five. It had been there since I was six. The hospital had the results. What they did not have was the institutional will to communicate a diagnosis to a young girl who was not, apparently, a research priority.
That specific failure is personal. But the architecture behind it — a medical system built around a body that was not mine, that dismissed nineteen years of symptoms because it lacked the framework to explain them — is structural. And structural problems require structural solutions. More funding. Better trials. Sex-disaggregated data as the default, not the exception. Medical education that includes the female body as the subject. And women — millions of them — who know enough about what they are owed to refuse to accept less.
The research gap is not a footnote. It is the story. Love, Nina ❤References
- NIH Office of Research on Women's Health. (2024). History of women's participation in clinical research. https://orwh.od.nih.gov/toolkit/recruitment/history
- Alabas, O. A., et al. (2017). Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction. Journal of the American Heart Association, 6(12). https://doi.org/10.1161/jaha.117.007123
- Guzikevits, M., et al. (2024). Sex bias in pain management decisions. PNAS, 121(33). https://doi.org/10.1073/pnas.2401331121
- Goulmamine, S., et al. (2024). Autoimmune health crisis: An inclusive approach to addressing disparities in women. IJERPH, 21(10), 1339. https://doi.org/10.3390/ijerph21101339
- Mirin, A. A. (2021). Gender disparity in the funding of diseases by the US NIH. Journal of Women's Health, 30(7). https://pmc.ncbi.nlm.nih.gov/articles/PMC8290307/
- Zucker, I., & Prendergast, B. J. (2020). Sex differences in pharmacokinetics predict adverse drug reactions in women. Biology of Sex Differences, 11(1), 32. https://doi.org/10.1186/s13293-020-00308-5
She Was Not
In the Study.
For decades, medicine built its knowledge of the human body from one body type. The treatments, the dosages, the diagnostic criteria — built on data that excluded half the population. This is not history. This is still happening.
I was six years old when a hospital diagnosed me with thalassemia. I was twenty-five when I found out. The file existed. The diagnosis existed. The knowledge that could have explained nineteen years of exhaustion, depression, and dismissal — existed. Nobody told me. That is not an accident of individual incompetence. It is the product of a medical system that was not built to look for answers in a body like mine.
This post is not about me. It is about the architecture of a problem that runs through every hospital, every drug trial, every diagnostic criterion, every textbook still in use in every medical school in the world. Modern medicine built its knowledge of the human body from a male body. And then it applied that knowledge to everyone.
Women are not small men. We metabolise drugs differently. We experience symptoms differently. We carry different risk profiles. And for most of the history of clinical medicine, none of this was considered important enough to study. I am not interested in softening that sentence.
Who Was in the Room?
Drag the timeline — watch who was, and was not, counted as human
The exclusion was policy. In 1977, the FDA issued guidelines explicitly recommending the exclusion of women of childbearing potential from Phase I and early Phase II drug trials. It was not reversed until 1993. Sixteen years of federally endorsed drug development based almost entirely on male biology. Those drugs are still in use today. [1]
The law changed. The practice did not fully follow. The NIH Revitalization Act of 1993 mandated the inclusion of women in all NIH-funded research. A Harvard Medical School study found that as of 2019 — twenty-six years later — women were still substantially underrepresented in trials for leading diseases. [2]
The heart attack that looks like anxiety. Women are 50% more likely to be misdiagnosed following a heart attack. Women under 55 are seven times more likely to be sent home without cardiac testing. Over one decade in England and Wales, these failures contributed to more than 8,000 avoidable deaths. The reason: diagnostic criteria built from male patient data. [3]
Pain is not believed when it comes from a woman. A 2024 PNAS study found that 38% of women received pain medication in the ER, compared to 47% of men with equivalent pain. Women spent 30 extra minutes in unaddressed pain. The mechanism: a gender-pain exaggeration bias. The historical term for this is hysteria. [4]
80% of autoimmune patients are women. The research does not reflect this. More than 80 autoimmune conditions exist. Approximately 80% of patients are women. Average time to diagnosis: 4.6 years and five different doctors. [5]
The medical system did not forget about women. It decided, explicitly and in writing, that women's bodies were too complicated to study. Then it treated us with the knowledge it had built without us.
The Funding Gap
100 dots = NIH research budget · Toggle to see distribution · Click any condition for the data
Female-dominant diseases are underfunded relative to burden in 75% of cases (Mirin, 2021).
Some conditions are funded so far below their disease burden that the disparity is not a gap — it is a chasm. Most women who have one of these have never been told how little research exists on what they are living with.
Ten Conditions. One System That Failed Them.
Click any card to see what is known — and what remains inexcusably unfunded
Demand 01Sex as a biological variable — in every study
Every drug trial, animal study, and cell culture experiment should analyse and report results by sex. The failure to do this has produced knowledge not generalisable to half the population. No one has been held accountable for the cost of that failure.
Demand 02Funding proportional to disease burden
Endometriosis: $4.30 per patient per year. HIV/AIDS: ~$2,583 per patient per year. Both serious diseases. The difference is not explained by scientific priority. It is explained by whose body was considered worth studying first.
Demand 03Medical training that includes women's symptom profiles
Medical schools still teach the "classic" heart attack as chest pain and left arm. This is predominantly male. As long as the male presentation is taught as default, physicians will keep sending women home. 8,000 avoidable deaths in a decade is not a statistic. It is a policy failure with a body count.
Demand 04Women who know what they are owed
The most powerful change is the number of women who walk into a clinical encounter knowing what the research gap means for them. Who know to ask whether their drug was tested on female subjects. Knowledge is not a substitute for systemic change. It is the starting point for demanding it.
I found my thalassemia diagnosis in a file at twenty-five. It had been there since I was six. The hospital had the results. What they did not have was the institutional will to communicate a diagnosis to a young girl who was not, apparently, a research priority.
That specific failure is personal. But the architecture behind it — a medical system built around a body that was not mine, that dismissed nineteen years of symptoms because it lacked the framework to explain them — that is structural. And structural problems require structural solutions.
More funding. Better trials. Sex-disaggregated data. Medical education that includes the female body as the subject, not the exception. And women — millions of them — who know enough about what they are owed to refuse to accept less.
The research gap is not a footnote. It is the story. Love, Nina ❤References
- NIH Office of Research on Women's Health. (2024). History of women's participation in clinical research. https://orwh.od.nih.gov/toolkit/recruitment/history
- AAMC. (2024). Why we know so little about women's health. https://www.aamc.org/news/why-we-know-so-little-about-women-s-health
- Alabas, O. A., et al. (2017). Sex differences following acute myocardial infarction. Journal of the American Heart Association, 6(12). https://doi.org/10.1161/jaha.117.007123
- Guzikevits, M., et al. (2024). Sex bias in pain management decisions. PNAS, 121(33). https://doi.org/10.1073/pnas.2401331121
- Goulmamine, S., et al. (2024). Autoimmune health crisis. IJERPH, 21(10), 1339. https://doi.org/10.3390/ijerph21101339
- Mirin, A. A. (2021). Gender disparity in NIH disease funding. Journal of Women's Health, 30(7). https://pmc.ncbi.nlm.nih.gov/articles/PMC8290307/